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Introduction
Extended-spectrum cephalosporins, b-lactam with b-lactamase inhibitor, carbapenems, fluoroquinolones, and aminoglycosides are common antimicrobial agents used in the treatment of bacterial infections. However, application of these antimicrobial agents can induce antimicrobial resistance through mutations and the transfer of mobile elements harboring resistance genes, thus increasing the incidence of drug-resistant bacteria. Some examples include extended-spectrum b-lactamase (ESBL)-producing bacteria carrying bla genes for cephalosporin resistance 1, 2 and fluoroquinolone-resistant bacteria with mutations in topoisomerases II and IV and altered expression of efflux pumps. 3, 4 The emergence of multidrug resistant (MDR) bacteria not only causes public health problems but also increases medical costs and the hospitalization, morbidity and mortality of patients. 5 MDR Gram-negative bacteria are major nosocomial pathogens and are increasing annually worldwide 6e11 and in Taiwan 12, 13 ; these species include ESBL-producing Klebseiella pneumoniae and Escherichia coli, MDR Pseudomonas aeruginosa, 14, 15 and pan-drug resistant Acinetobacter baumannii. 16 Carbapenems have recently been replaced the extended-spectrum cephalosporins to treat ESBL-producing bacteria; accordingly, carbapenem resistance has been observed in P. aeruginosa (i.e., imipenem) 17 and A. baumannii (CRAB). 18, 19 In Taiwan, CRAB isolates have increased gradually, with the highest in central Taiwan. 20 In this study, we analyzed the resistance profile of major Gram-negative bacteria, the consumption of antimicrobial agents and the correlation between antimicrobial usage and development of resistance.
Materials and methods

Retrospective study
All information was collected from Chiayi Branch, Taichung Veterans Hospital from 2003 to 2011. The hospital has 445 beds, including 24 beds for intensive care units, 40 beds for the respiratory care ward, 250 beds for general in-patients, and 225 beds for psychiatry patients. The hospital also has a 246-bed nursing home.
Bacterial identification and antimicrobial susceptibility test
Clinical isolates of A. baumannii, E. coli, K. pneumoniae, P. aeruginosa, and P. mirabilis were identified using the Phoenix and VITEK system in the Medical Laboratory Division. The antimicrobial susceptibility to the antimicrobial agents was determined according to the guidelines of Clinical and Laboratory Standards Institute. 21 The antimicrobial agents analyzed included: amikacin, gentamicin, and isepamicin (aminoglycosides); cefazolin, cephradine, and cephalexin (first-generation cephalosporins); flomoxef, cefuroxime, cefoxitin, ceftazidime, ceftriaxone, and cefepime (extended-spectrum cephalosporins); imipenem, meropenem, and ertapenem (carbapenems); ciprofloxacin, levofloxacin, and moxifloxacin (fluoroquinolones); ampicillin/sulbactam, amoxicillin/clavulanic acid, piperacillin, piperacillin/tazobactam (penicillins and penicillin with blactamase inhibitor); and tigecycline. The defined daily dose represents the antimicrobial usage of 1000 patients and was used for the statistical analysis.
Statistical analysis
Linear regression was performed to determine the correlation coefficient (r) of antimicrobial agent consumption and antimicrobial resistance of each species associated with specific years. Furthermore, correlation coefficients of antimicrobial agent consumption and antimicrobial resistance in each species were calculated, and a t test for was applied to ascertain significant differences (p < 0.05).
Results
Clinical isolates of five Gram-negative bacteria
The number of clinical isolates differed among the species with the highest for P. aeruginosa, followed by E. coli, A. baumannii, K. pneumoniae, and P. mirabilis (Table 1) . Although the clinical isolates of each species differed annually, maximal number was observed for P. aeruginosa, E. coli, and K. pneumoniae in 2008 and for P. mirabilis in 2009. A. baumannii clinical isolates increased annually from 2003 to 2011. These five species differed in prevalence of bloodstream isolates from the highest for E. coli (13.5%), followed by K. pneumoniae (9.8%), A. baumannii (5.9%), P. mirabilis (5.9%) and P. aeruginosa (3.6%). Interestingly, A. baumannii showed an increase in bloodstream isolates and mainly were CRAB (88%).
Consumption of antimicrobial agents
The consumption level of five major antimicrobial groups differed with a gradual reduction in aminoglycosides (r Z À0.88, p < 0.01) and first-generation cephalosporins (r Z À0.92, p < 0.01), an annual increase in extendedspectrum cephalosporins (r Z 0.92, p < 0.01) and carbapenems (r Z 0.93, p < 0.01), with an exceptional use of fluoroquinolones and penicillins in 2006 and 2007, respectively (Table 2 ). Furthermore, the consumption level of antimicrobial agents in each group varied. For the aminoglycosides, an increase in amikacin and reduction in gentamicin were observed. With regard to the fluoroquinolones, a significant reduction in ciprofloxacin and increase in levofloxacin were found (p < 0.05). Of penicillins, ampicillin/sulbactam and piperacillin reached the maximal consumption in 2007 and 2008, respectively, and then decreased in contrast to the increase in the use of amoxicillin/clavulanic acid and piperacillin/tazobactam annually. For the extended-spectrum cephalosporins, a significant increase in ceftriaxone, cefoxitin, and flomoxef and decrease in cefuroxime were observed. The consumption level of imipenem and meropenem was decreased since 2008 and 2009, respectively, while an increase in ertapenem was observed at the same period.
Antimicrobial susceptibility
The antimicrobial agent selected to treat infections depend on the bacterial species involved. Therefore, antimicrobial resistance and its prevalence differed among these five species (Table 3) . Comparing the antimicrobial resistance of E. coli, K. pneumoniae, and P. mirabilis of Enterobacteriaceae, E. coli showed significant increase in the resistance (over 40%; r > 0.9, p < 0.05) to ampicillin/sulbactam, cefazolin, cefoxitin, ceftazidime, and ceftriaxone of the b-lactam antimicrobials, and to ciprofloxacin and levofloxacin of the fluoroquinolones. In contrast, the average resistance rate ( 20%) was for cefepime, meropenem, and piperacillin/tazobactam. All K. pneumoniae isolates exhibited significantly increased resistance (r > 0.70, p < 0.05) to all antimicrobial agents, except gentamicin, cefepime, levofloxacin, and meropenem. These two species differed in the antimicrobial resistance rate. Higher resistance rates were observed in E. coli for ampicillin/sulbactam, ceftriaxone, ciprofloxacin and levofloxacin and in K. pneumoniae for cefepime, meropenem and piperacillin/tazobactam. In contrast to the above two species, P. mirabilis displayed annual increases in resistance only to amikacin (r Z 0.70, p < 0.05).
In P. aeruginosa, resistance rate was increased in ceftazidime, piperacillin/tazobactam, and carbapenems of meropenem (p Z 0.03) and imipenem (p Z 0.08), but reduced in aminoglycosides (r < À0.8, p < 0.05). All A. baumannii isolates showed the highest resistance rate to all antimicrobials examined, particularly ampicillin/sulbactam, meropenem, ciprofloxacin, and levofloxacin, with nearly 90% in recent years. However, an annual increase in resistance was only found to be significant for imipenem and meropenem (r > 0.9, p < 0.05), ciprofloxacin (r Z 0.96, p < 0.001) and ampicillin/sulbactam (r Z 0.95, p < 0.001).
Association of antimicrobial resistance rate and antimicrobial dosage
Although 26 antimicrobial agents and five bacterial species were investigated, a significant correlation between the antimicrobial resistance rate of six antimicrobial agent Total clinical isolates  2003  394  453  152  271  105  1375  2004  459  561  226  268  90  1604  2005  653  748  371  310  224  2306  2006  570  800  458  442  296  2566  2007  497  551  417  416  165  2046  2008  545  638  482  348  218  2231  2009  546  569  445  380  333  2273  2010  527  496  346  396  202 groups and antimicrobial consumption was observed; for examples, use of extended-spectrum cephalosporins as well as reduced use of aminoglycoside and first-generation cephalosporins and development of related resistance in E. coli; development of resistance to all five antimicrobial groups used and reduced consumption of aminoglycosides in K. pneumoniae; use of aminoglycosides, extendedspectrum cephalosporins, and piperacillin/tazobactam to develop resistance to these antimicrobial agents in P. aeruginosa; use of carbapenem and development of resistance to imipenem and meropenem in A. baumannii (Table 4) .
Discussion
Antibiotic-resistant bacteria in humans have been related to maternal and environmental microbial origins 22 and can transfer from animals to humans through consumption of contaminated meats and other products. In this study, the major antimicrobial agents, for which significant increases in consumption were found, included extended-spectrum cephalosporins and carbapenems, although aminoglycoside and first-generation cephalosporins consumption significantly decreased ( Table 2 ). The association of antimicrobial consumption with the development of antimicrobial resistance has been reported to be dependent on the species and antimicrobial agent. The aminoglycoside consumption developed resistance to amikacin in K. pneumoniae and resistance to gentamicin in E. coli, resistance to both antimicrobials in P. aeruginosa, no resistance to both in A. baumannii and P. mirabilis (Table 4) . These results also partially confirmed the report that aminoglycoside resistance was not associated with its consumption in Gram-negative bacteria. 23 Despite decreases in the consumption of fluoroquinolones, gentamicin and trimethoprim/sulfonamide, the resistance to these agents increased in E. coli. 24 Ciprofloxacin consumption could significantly increase the resistance to ceftazidime in K. pneumoniae, resistance to ceftazidime, ciprofloxacin or imipenem in A. baumannii and resistance to imipenem, ceftazidime and ciprofloxacin in P. aeruginosa. 25 Consumption of antimicrobial agents to develop resistance to other antimicrobial agents also occurred in E. coli; for example: cephalosporin use and nitrofurantoin resistance; amoxicillin use and fluoroquinolone resistance; and fluoroquinolone use and ampicillin resistance. 26 An increasing use of extended-spectrum cephalosporins (particularly ceftazidime) could develop ceftazidime resistance in K. pneumoniae, Enterobacter spp. and P. aeruginosa in humans.
27e31 Such correlation between application of third-and fourth-generation cephalosporins and increase of extended-spectrum cephalosporinase-producing E. coli has been reported in pigs, 32 implying that the ESBL-producing E. coli can transfer from the contaminated meat and products to humans. In the present study, correlation between extended-spectrum cephalosporin use and development of resistance to these antimicrobials were only observed in P. aeruginosa, E. coli, and K. pneumoniae, not in P. mirabilis and A. baumanii (Table 4) . Because of the dissemination and spread of ESBLproducing bacteria, carbapenem has been replaced extended-spectrum cephalosporins as therapeutic drugs for the bacterial infection. In Germany, an increase in third-generation cephalosporin-resistant E. coli and K. pneumoniae was accompanied by a twofold increase in carbapenem consumption and then increased carbapenem resistance in K. pneumoniae and A. baumannii. 33 In the present study, a significant correlation between carbapenem consumption and resistance to these agents was also observed in K. pneumoniae and A. baumannii (Table 4 ). In Taiwan, CRAB was found to be, on average, 46% in hospitals 20 and has increased meropenem resistance to 48.4%. 34 Our data demonstrated a higher resistance to meropenem and imipenem in A. baumannii, with a prevalence of 69% and 77%, respectively. This higher CRAB rate is possibly because the patients are mainly veterans with an average age of 66 years in the nursing home of our hospital. Additionally, the gradually increasing consumption of piperacillin/tazobactam for treatment was correlated with an increase in piperacillin/tazobactam resistance in K. pneumoniae and P. aeruginosa (Table 4) .
To inhibit the development of antimicrobial resistance due to antimicrobial agent-inducing mutations, the lowest concentration (mutant prevention concentration, MPC) that prevents the growth of resistant colonies is commonly used. Therefore, an antimicrobial concentration above MPC during therapy can inhibit mutant subpopulation amplification. 35 An analysis of MPC for E. coli ATCC 25922 varied from 2 Â minimal inhibitory concentration (MIC) for trovafloxacin, 4 Â MIC for ciprofloxacin, norfloxacin and ofloxacin, 8 Â MIC for clinafloxacin and levofloxacin, 16 Â MIC for sparfloxacin and 32 Â MIC for nalidixic acid at 37 C under aerobic conditions. 34 The MPC/MIC value of urinary tract infection E. coli was 16 for ciprofloxacin resistance (4 mg/L) and up to 5 for ciprofloxacin susceptibility (1 mg/ L). 36 Furthermore, P. aeruginosa showed significant correlation between ciprofloxacin use and its resistance development. 35 In our study, the decrease in quinolone consumption since 2006 was associated with an increase in its resistance in A. baumannii, E. coli, K. pneumoniae, and P. aeruginosa, possibly due to the increasing levofloxacin consumption ( Table 2 ). The ciprofloxacin MPC was two-fold lower than that of levofloxacin; therefore, the increased use of levofloxacin possibly induced bacterial resistance. In an effort to reduce antimicrobial-resistant bacteria, the extensive implementation of antimicrobial stewardship has significantly decreased the consumption of secondgeneration cephalosporins, carbapenems, and aminoglycoside and reduced the appearance of methicillin-resistant Staphylococcus aureus and antimicrobial-resistant Serratia marcescens. 37 Therefore, a effective implementation of antimicrobial use and MPC are needed to reduce the development of antimicrobial resistance.
In Enterobacteriaceae, K. pneumoniae developed resistance to all antimicrobial groups most easily, followed by E. coli. This higher resistance may be due to the thick polysaccharide capsule in general around K. pneumoniae. No correlation between antimicrobial consumption and its resistance was observed in P. mirabilis, which is frequently considered to be contamination. However, MDR P. mirabilis is commonly identified in this hospital. P. aeruginosa developed resistance to b-lactam antimicrobials and aminoglycosides, while A. baumanii only developed resistance to carbapenems associated with their use.
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